Table 3: Frequency of metabolic and cardiovascular comorbidities observed by type of ARV and duration of treatment.

Comorbidities Total NNRTI-based PI-based/ rescue p value < 5 years ≥ 5 years p value
(n=233) (n=72) (n=89) (n=216)
Dyslipidemia, n (%) 157 (51.5) 122 (52.4) 35 (48.6) 0.336 39 (43.8) 118 (54.6) 0.005
Obesity, n (%) 34 (11.1) 24 (10.3) 10 (13.9) 0.258 12 (13.5) 22 (10.2) 0.259
Excess weight, n (%) 127 (41.6) 102 (43.8) 25 (34.7) 0.109 36 (40.5) 91 (42.1) 0.444
Diabetes mellitus, n (%) 22 (7.2) 19 (8.2) 3 (4.2) 0.191 3 (3.4) 19 (8.8) 0.071
Hypertension, n (%) 27 (8.9) 23 (9.9) 4 (5.6) 0.188 4 (4.5) 23 (10.6) 0.061
Cardiovascular diseases, n (%) 10 (3.3) 6 (2.6) 4 (5.6) 0.189 1 (1.1) 9 (4.2) 0.158
Impairment of renal function, n (%) 19 (6.2) 12 (5.1) 7 (9.7) 0.131 4 (4.5) 15 (6.9) 0.301

Back to Article